Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Lilly drops $55M for access to new class of diabetes drugs
Lilly drops $55M for access to new class of diabetes drugs
Lilly drops $55M for access to new class of diabetes drugs
Submitted by
admin
on June 8, 2017 - 9:58pm
Source:
BioPharma Dive
News Tags:
Eli Lilly
diabetes
dual amylin calcitonin receptor agonists
DACRAs
Key Bioscience
KBP-042
Headline:
Lilly drops $55M for access to new class of diabetes drugs
Do Not Allow Advertisers to Use My Personal information
